Evidence map›Paper›PMID 32237190›Full record

ArticleDermatologic therapy2020

What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy.

Andy Goren, John McCoy, Carlos G Wambier, Sergio Vano-Galvan, Jerry Shapiro, Rachita Dhurat, Kenneth Washenik, Torello Lotti

4 registry-linked trialsAbstract readLetter
In one paragraph

Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04368897 withdrawnnot on this map

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

TypeobservationalSponsorApplied Biology, Inc.Ran2020 to 2022Enrolled0ConditionsSARS-CoV 2, COVID, COVID-19, Androgenetic AlopeciaArmsCAG length <22, CAG length >=22
NCT04446429 nacompletednot on this map

Anti-Androgen Treatment for COVID-19

TypeinterventionalSponsorApplied Biology, Inc.Ran2020 to 2021Enrolled268ConditionsCOVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate CancerArmsProxalutamide, Standard of Care
NCT04728802 phase3completednot on this mapstarted 2021, after this paper: background citation

Proxalutamide Treatment for Hospitalized COVID-19 Patients

TypeinterventionalSponsorApplied Biology, Inc.Ran2021 to 2021Enrolled645ConditionsCovid19, SARS (Severe Acute Respiratory Syndrome)ArmsProxalutamide, Placebo
NCT04898166 completednot on this map

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19)

Typeobservational_patient_registrySponsorSyeda Mahanum AliRan2020 to 2021Enrolled300ConditionsAndrogenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Complementary Strategies to Promote Hair Regrowth in Post-COVID-19 Telogen Effluvium.Clinical, cosmetic and investigational dermatology · 2022
    Review
  9. Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review.Androgens: clinical research and therapeutics · 2022
    Review
  10. Review
  11. Review
  12. Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  13. Article
  14. The COVID-19 pandemic and its skin effects.Canadian family physician Medecin de famille canadien · 2021
    Review
  15. Extraordinary claims without extraordinary evidence: controversy on anti-androgen therapy for COVID-19.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021
    Article
  16. Review
  17. COVID-19 pandemic: what about the gonads?Hormones (Athens, Greece) · 2021
    Review
  18. Review
  19. Is COVID-19 Gender-sensitive?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021
    Review
  20. Reply to comment on: The Gabrin sign.Journal of the American Academy of Dermatology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Andy GorenApplied Biology, Inc., Irvine, California, USA.ORCID https://orcid.org/0000-0002-8190-2289
John McCoyApplied Biology, Inc., Irvine, California, USA.ORCID https://orcid.org/0000-0003-1577-9910
Carlos G WambierDepartment of Dermatology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.ORCID https://orcid.org/0000-0002-4636-4489
Sergio Vano-GalvanTrichology Unit, Dermatology Department, Ramon y Cajal Hospital, IRYCIS, University of Alcala, Madrid, Spain.
Jerry ShapiroRonald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA.
Rachita DhuratDepartment of Dermatology, LTM Medical College & Hospital Sion, Mumbai, India.
Kenneth WashenikRonald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA.
Torello LottiDepartment of Dermatology and Venereology, University of Rome "G.Marconi", Rome, Italy.ORCID https://orcid.org/0000-0003-0840-1936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAlopeciaAnimalsCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFemaleHumansMalePandemicsPneumonia, ViralReceptors, AndrogenRisk FactorsSex FactorsReceptors, Androgen

Identifiers

PMID32237190
PMCPMC7228378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.